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Abstract 
Background: Central venous catheters (CVCs) are commonly secured with sutures which are associated with micro‑
bial colonization and infection. We report a comparison of a suture‑free system with standard sutures for securing 
short‑term CVC in an international multicentre, prospective, randomized, non‑blinded, observational feasibility study. 
Consented critical care patients who had a CVC inserted as part of their clinical management were randomized to 
receive either sutures or the suture‑free system to secure their CVC. The main outcome measures were CVC migration 
(daily measurement of catheter movement) and unplanned catheter removals.
Results: The per cent of unplanned CVC removal in the two study groups was 2% (suture group 2 out of 86 patients) 
and 6% (suture‑free group 5 out of 85 patients). Both securement methods were well tolerated in terms of skin irrita‑
tion. The time and ease of application and removal of either securement systems were not rated significantly differ‑
ent. There was also no significant difference in CVC migration between the two securement systems in exploratory 
univariate and multivariate analyses. Overall, 42% (36 out of 86) of the CVC secured with sutures and 56% (48 out of 
85) of the CVC secured with the suture‑free securement system had CVC migration of ≥ 2 mm.
Conclusions: The two securement systems performed similarly in terms of CVC migration and unplanned removal 
of CVC; however, the feasibility study was not powered to detect statistically significant differences in these two 
parameters.
Trial registration: ISRCTN, ISRCTN13939744. Registered 9 July 2015, http://www.isrct n.com/ISRCT N1393 9744.
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Background
Central venous catheters (CVCs) are widely used in hos-
pitalized patients, but are associated with infections, and 
mechanical and chemical complications [1, 2]. Sutures 
are frequently used to secure CVC onto the skin, despite 
not being recommended [3, 4]. Application of sutures 
carries a risk of injury and also disrupts the skin at the 
insertion site. More recently, it has been demonstrated 
that sutures serve as a nidus for microbial growth and 
become heavily colonized [5]. These micro-organisms 
may act as a source of catheter-related infections (CRI) 
including blood stream infection [6].
Alternative methods to sutures for short-term CVC 
securement are available. These include staples, anchor 
devices, catheter holders, tissue adhesives, tapes and 
dressings. However, evidence of their efficacy in secur-
ing a short-term CVC is limited, with the majority of 
available data derived from small-scale studies and 
clinical observations [7, 8]. Furthermore, most of the 
evidence is derived from peripheral, arterial and periph-
erally inserted central venous catheter (PICC) secure-
ment. Data on the efficacy of these devices for securing 
short-term CVC in various anatomical locations are also 
limited.
Our aim was to evaluate a new adhesive suture-free 
securement system and to compare it to sutures and a 
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transparent film dressing in securing short-term CVC. 
The catheters were observed daily throughout their 
placement, and the main outcome measures were cath-
eter migration at the skin insertion site (i.e. partial cath-
eter dislodgement) and unplanned CVC removals (i.e. 
complete catheter dislodgement).
Methods
This international, multicentre, prospective, observa-
tional, randomized, non-blinded feasibility study was 
carried out on four intensive care units (ICU) in three 
European countries. Ethical committee approval for this 
study was sought in each country. In the UK, approval 
was granted by the National Research Ethics Service 
Committee North West—Greater Manchester South 
(REC Reference 15/NW/0185), in Spain by Institut Cat-
ala de la Salut, Hospital Universitari Arnau de Vilanova, 
and in France by the Comité de Protection des Personnes 
Ouest III (Protocol # 15.04.19). The trial was registered 
with the International Standard Randomized Controlled 
Trials Number (ISRCTN 13933744).
Study population
Between August 2015 and January 2017, adult patients 
on a study ICU, who required a single, short-term, 
non-cuffed, non-tunnelled central venous catheter 
(CVC), were considered for inclusion. Exclusion criteria 
included: confusion [patients who had a positive confu-
sion assessment method for the ICU (CAM-ICU) score 
or if confusion was expected after sedation was stopped]; 
excessive perspiration (skin became moist within 2  min 
of drying); non-adherent skin, burn, trauma or other con-
dition affecting the skin integrity at the potential CVC 
insertion site; uncorrected bleeding diathesis; allergy to 
device components; more than one catheter inserted at 
the same location; or pregnant or breastfeeding women. 
In the UK and Spain, participant written consent was 
obtained, and in France, a verbal no objection for study 
participation was confirmed as specified by local ethical 
approval. Patient demographics and clinical details were 
recorded on enrolment.
Catheter and securement placement
Consented patients, who met the study criteria, were 
randomized to receive either a 3M™ PICC/CVC Secure-
ment Device (3M Health Care, Minnesota, USA) (Fig. 1) 
or sutures to secure their CVC onto their skin. A Tega-
derm™ IV Advanced Securement (3M Health Care) 
dressing was then used to cover the CVC insertion site 
in both groups, and the size was recorded. The num-
ber of sutures and their application were according to 
local practice. The securement system and dressing 
were applied as per the manufacturer’s instruction. In 
summary, the patient’s skin was dried prior to applica-
tion. Lumens of CVC were placed into the channels 
of the moulded plastic securement device and weaved 
under the plastic arm. The lumens were then secured 
into position with an integrated tape strip. The secure-
ment device was held in the adopted position against 
the patient’s skin, and the adhesive base was exposed. 
The dressing was applied to cover both the insertion site 
and the securement device. Staff received training on 
the application and removal of the securement device 
and dressing. Insertion procedure details including hair 
removal, site and ease of insertion and the time required 
were recorded. Catheter characteristics, including French 
gauge, the number of lumens and the type, were also 
noted. The time required to apply the selected CVC 
securement and the ensuing length of the external CVC 
relative to the insertion site were also determined.
Catheter migration and unplanned/planned removals
The external length of CVC was measured daily and 
following dressing or securement device replacement. 
The measurement was taken from where the catheter 
entered the skin (the CVC skin entry point) to the start 
of the CVC hub. The daily CVC migration was calculated 
from transforming any measured daily migration (i.e. 
inward or outward CVC movement) as a positive value. 
The catheter migration range was deduced from the dif-
ference between the lowest and the greatest measured 
external CVC length for each patient. Reasons for CVC 
removal and any unresolved catheter occlusions and 
the number of patients requiring an alternative catheter 
securement method were recorded.
Adverse events
Any adverse events and inoculation injuries which 
occurred during the CVC insertion and application of 
sutures were recorded.
Securement and dressing application, removal 
and replacement
Daily assessment included securement device and dress-
ing integrity and adherence onto the skin and catheter, 
and the number of dressing changes and reasons for 
replacement.
The ease of removal and replacement of the secure-
ment systems were evaluated, and the time and reasons 
for performing these procedures were also recorded.
Patient and of the catheter insertion site assessments
Daily assessment included patient comfort (pain score) 
and sedation score, and erythema, swelling and bleeding 
at the catheter insertion site.
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Data analysis
Patients were enrolled into the study for the duration 
their CVC was in  situ and remained as an inpatient. 
They were followed up to either CVC removal or dis-
charge. Some patients were withdrawn from the study. 
Reasons for this included discharge within 24  h fol-
lowing CVC placement or before the first post-base-
line assessment was completed. These patients were 
excluded from the final study analysis.
This study was designed as a feasibility study and 
therefore was not powered to demonstrate statistically 
significant differences. Patient background data were 
analysed with Fisher’s exact and Mann–Whitney tests. 
The primary outcome measure, the number of com-
plete CVC dislodgements, and the secondary outcome 
measure, the number of partial CVC dislodgements, 
were analysed by Fisher’s exact and Pearson’s Chi-
square tests.
Results
Patient and catheter placement characteristics
The CONSORT flow diagram for screened and enrolled 
patients is presented in Fig.  2. In total, 186 patients 
met the study criteria, and were consented and rand-
omized to receive either CVC securement method. Of 
these, 171 patients had at least one daily assessment 
recorded and were included in the data analysis. Patient 
and clinical characteristics were not found to be differ-
ent in both groups, except for the number with a tra-
cheostomy which was higher in the suture-free group 
(Table  1). The presence of a tracheostomy did not 
have an effect on CVC dislodgement nor daily CVC 
migration.
CVC characteristics including their size, number 
of lumen, hair removal, anatomical location and time 
required for insertion were not significantly different 
in both groups except for the number of patients who 
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Fig. 1 3M™ PICC/CVC Securement Device consisting of a moulded plastic device (size 5.1 cm × 5.4 cm) integrated onto a breathable base with 
a silicone adhesive (Tegaderm™ IV Advanced Securement device, on the left) and a soft cloth bordered transparent film dressing (Tegaderm™ IV 
Advanced Securement dressing, on the right; 8.5 cm × 11.5 cm)
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had a box clamp (a device that grips the catheter below 
the hub and has flanges to accommodate sutures) 
which was higher in the suture group (Table  2). Box 
clamp use was associated with longer sections of 
externally protruding catheters following CVC inser-
tion. The median external length of catheter following 
Assessed for eligibility (n=346)
Withdrawals (n=3):
Did not meet the inclusion criteria 
following CVC inseron n=2
No follow-up assessment n=1
Withdrawals (n=12):
Death or transfer <24 h n=2
Did not meet the inclusion criteria 
following CVC inseron n=10
Excluded (n=160):
Did not meet the study inclusion criteria n=40
Declined to parcipate n=47
Surgery/admission rescheduled n=13
Unable to consent n=23
Reason not known n=37
Recruited and randomized (n=186)
Suture free group (n=97)Suture group (n=89)
Completed study and eligible for 
inclusion in data analysis (n=86)
Completed study and eligible for 
inclusion in data analysis (n=85)
Fig. 2 Study CONSORT flow diagram. Critical care patients in four study centres were screened and enrolled patients randomized to receive 
either sutures and a Tegaderm™ IV Advanced dressing (suture group) or 3M™ PICC/CVC Securement Device + Tegaderm™ IV Advanced dressing 
(suture‑free group) to secure a short‑term central venous catheter (CVC) onto the skin
Table 1 Clinical and patient characteristics
Patients were randomized to receive either sutures and a Tegaderm™ IV Advanced dressing (suture group) or 3M™ PICC/CVC Securement Device + Tegaderm™ IV 
Advanced dressing (suture-free group) to secure a short-term central venous catheter (CVC) onto the skin [n = number of patients or catheter days (IQR or %)]
APACHE II score, the acute physiology and chronic health evaluation score; BMI, body mass index; ECMO, extracorporeal membrane oxygenation; RASS score, the 
Richmond Agitation–Sedation Scale score
a Mann–Whitney test; bFisher’s exact test
Suture group (n = 86 patients) Suture-free group (n = 85 patients) p value
Median (IQR) age (years) 66 (56.3; 74) 62 (51; 72) 0.222a
Median (IQR) APACHE II score 23 (15.5; 32) 21 (14; 29) 0.271a
Median (IQR) BMI 26.7 (23.0:31.9) (n = 80) 26.8 (24.3:30.5) (n = 73) 0.509a
Male‑to‑female ratio (%) 59:27 (68.6:31.4) 68:17 (80.0:20.0) 0.115b
Number of patients (%) receiving
Sedative agents 38 (44.2) 47 (55.3) 0.170b
Paralysing agents 11 (12.8) 7 (8.2) 0.456b
Endotracheal tube 43 (50.0) 50 (58.8) 0.284b
Tracheostomy 7 (8.1) 16 (18.8) 0.046b
Mechanical ventilation 46 (53.5) 55 (64.7) 0.162b
Non‑invasive ventilation 18 (20.9) 15 (17.6) 0.699b
Haemodialysis 9 (10.5) 15 (17.6) 0.194b
ECMO 2 (2.3) 2 (2.4) 1.00b
RASS score (%) (n = 494 catheter days) (n = 580 catheter days)
1 or above 30 (6.1) 33 (5.7) 0.539b
0 227 (46.0) 249 (42.9)
− 1 or less 237 (48.0) 298 (51.4)
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insertion was 11.1  mm (95% CI 5.6, 16.7) with a box 
clamp and 3.9  mm (95% CI 1.8, 6.0) without a box 
clamp (p = 0.012, Mann–Whitney test). The median 
number of sutures applied was 2.9 (95% CI 2.6, 3.9) in 
the 27 patients who received a box clamp as compared 
to 2.0 (95% CI 1.9; 2.1) in the 55 patients without a 
clamp (p < 0.0001, Mann–Whitney test).
Catheter migration and unplanned/planned removals
Overall, there was no significant difference in CVC 
migration between the two securement systems, with 
41.9% (36 out of 86) of CVC secured with sutures and 
56.5% (48 out of 85) of CVC secured with suture-free 
securement system having CVC migration of ≥ 2  mm 
(p = 0.056; Pearson’s Chi-square) (Table 3).
Unplanned removal of a CVC occurred in 2 out of 86 
(2.3%) patients in the suture group and 5 out of 85 (5.9%) 
patients in the suture-free group (p = 0.277, Fisher’s 
Table 2 Central venous catheter (CVC) and CVC securement characteristics in the two study groups
Patients were randomized to receive either sutures and a Tegaderm™ IV Advanced dressing (suture group) or 3M™ PICC/CVC Securement Device + Tegaderm™ IV 
Advanced dressing (suture-free group) to secure their CVC onto the skin [n = number of CVC or CVC days (IQR or %)]
IJ, internal jugular vein; SC, subclavian vein; FM, Femoral vein
a Mann–Whitney test; bFisher’s exact test; cPearson’s Chi-square; dexternal CVC length measured in millimetre from the CVC skin entry point to the moulded junction 
of the CVC hub
Suture group (n = 86) Suture-free group (n = 85) p value
Median (IQR) size (Fr gauge) of CVC 7 (7; 8.5) 7 (7; 8.5) 0.818a
Median (IQR) number of lumens 3 (3; 4) 3 (3; 4) 0.897a
Insertion site IJ:SC:FM (%) 34:28:24 (39.5:32.6:27.9) 36:25:24 (42.4:29.4:28.2) 0.895b
Hair removed from insertion site (%) 15 (17.4) 12 (14.1) 0.676b
Number of CVC with a box clamp (%) 27 (31.4) 3 (3.5) < 0.0001b
Mean (95% CI) external CVC length (mm) immediately following CVC  insertiond 6.2 (3.9; 8.5) (n = 84) 16.2 (10.0; 22.3) (n = 84) 0.299a
No. of catheter days with assessment (%) 532 (91.3) 643 (90.4) 0.610c
Mean (95% CI) duration (days) the CVC in place 6.8 (5.5; 8.1) 8.4 (6.6; 10.1) 0.162a
Median (IQR) time (min) to apply CVC securement 3 (2; 6.5) (n = 79) 5 (3; 5) (n = 78) 0.184a
Median (IQR) time (min) to replace CVC dressing/securement device 7 (5; 10) (n = 90) 10 (5; 10) (n = 129) 0.006a
Median (IQR) time (min) to remove CVC dressing/securement device 3 (2.5; 5) (n = 25) 2 (1; 4) (n = 29) 0.08a
Table 3 Migration of  short-term central venous catheters (CVCs) when  secured with  sutures and  a  Tegaderm™ IV 
Advanced dressing (suture group) or 3M™ PICC/CVC Securement Device + Tegaderm™ IV Advanced dressing (suture-free 
group) [n = number of observations or CVC (%)]
Movement in millimetre Suture securement group [n = no. 
of observations or CVC (%)]
Suture-free securement group [n = no. 
of observations or CVC (%)]
p value 
(Pearson’s Chi-
square)
Daily movement No. of observations (n = 523) No. of observations (n = 624)
0–1 455 (87.0%) 539 (86.4%) 0.686 (1.5)
2–5 55 63
6–10 8 11
> 10 5 11
Movement due to replacement No. of replacement (n = 84) No. of replacement (n = 114)
0–1 67 (79.8%) 96 (84.2%) 0.366 (3.2)
2–5 17 13
6–10 1 3
> 10 1 2
CVC movement range No. of CVC (n = 86) No. of CVC (n = 85)
0–1 50 (58.1%) 37 (43.5%) 0.146 (3.9)
2–10 27 38
> 10 9 10
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exact test). Four CVC in the suture group (days 5, 7, 12 
and 14) and five CVC in the suture-free group (days 8, 35 
and three on day 11) were removed due to fever or sus-
pected infection which were not subsequently confirmed 
as being CVC related. Occlusion or non-functional CVC 
led to CVC removal on one occasion in both securement 
groups. In the suture-free group, thrombus formation in 
one catheter resulted in the CVC being removed.
Subgroup exploratory multivariate analysis
Exploratory multivariate analysis was carried out on the 
daily CVC migration data. Significantly less daily CVC 
migration was demonstrated in the suture group when a 
box clamp was used [6.5% of the CVC daily movement 
recorded ≥ 2  mm (9 out of 139 observations)] as com-
pared to no box clamp application [15.4% of the CVC 
daily movement recorded ≥ 2 mm (59 out of 384 obser-
vations); p = 0.008, Fisher’s exact test].
CVC migration was also more prevalent when a 
4-lumen CVC was inserted and secured with sutures in 
comparison with a 3-lumen CVC secured with sutures 
[36 out of 179 (20.1%) vs. 31 out of 335 (9.3%) daily 
observations recorded movement ≥ 2  mm, respectively; 
p = 0.001]. However, in the suture-free group the dif-
ference in the frequency of CVC migration between a 
4-lumen and 3-lumen CVC was not significant [16 out 
of 149 (10.7%) vs. 68 out of 473 (14.4%) daily observa-
tions recorded catheter movement ≥ 2 mm, respectively; 
p = 0.275].
Adverse events
One adverse event was recorded in the suture-free group, 
when a catheter became twisted. Two incidences of nee-
dlestick injury occurred in one study centre during CVC 
insertion, both in the suture securement study group.
Securement and dressing application, removal 
and replacement
There were no significant differences in the mean number 
of dressings used per CVC, with 2.24 (95% CI 1.93, 2.56) 
and 2.73 (95% CI 2.29, 3.17) in the suture and suture-free 
groups, respectively (p = 0.109, Mann–Whitney test). The 
causes for dressing replacement in the suture and suture-
free group were also comparable, with 27.4% and 28.0% 
of replacement being scheduled and 31% and 25.5% of 
replacement due to excessive dressing lift, respectively. 
The suture-free securement device had to be repositioned 
on two occasions (two separate patients) due to incor-
rect application of the securement system. Two patients 
(2.3%) had sutures which became detached during the 
study, and the dressing became completely detached 
on two occasions (in separate patients). The suture-free 
securement system was replaced in three occasions (in 
separate patients) due to system detachment.
The time to apply and remove sutures and a dressing 
or a suture-free securement device and a dressing were 
not significantly different (Table  2). However, the time 
required to replace the dressing plus suture-free secure-
ment device was longer than replacement of the dress-
ing in the suture group (p = 0.006, Mann–Whitney 
test). Suture securement application was rated easy or 
reasonable in 54 out of 55 (98.2%) applications assessed 
compared with 48 out of 54 (88.9%) suture-free secure-
ment system applications (p = 0.048, Fisher’s exact test). 
Removal was rated easy or reasonable in 24 out of 25 
(96%) of suture securement removals and 28 out of 29 
(96.6%) of the suture-free securement system removals. 
Dressing replacement in the suture group was rated easy 
or reasonable in 99 out of 100 (99%) user assessments 
in comparison with 117 out of 131 (89.3%) assessments 
of the suture-free securement device (p = 0.002, Fisher’s 
exact test).
Patient comfort and assessment of the catheter insertion 
site
The assessment of patient pain score during the dress-
ing and securement system removal or replacement was 
not significantly different in both study groups (p = 0.192, 
Kruskal–Wallis test). In addition, the daily observation 
for erythema under the dressing was not scored dif-
ferently in both groups. Seventeen out of 86 patients in 
the suture group and 19 out of 85 patients in suture-free 
group patients had erythema around the CVC insertion 
site (p = 0.711, Fisher’s exact test). Similarly, the other 
daily assessments of the CVC insertion sites, includ-
ing swelling (3.5% vs. 1.2%), bruising (5.8% vs. 3.5%), or 
discharge (37.2% vs. 47.1%) whilst the CVC were in situ, 
were not significantly different between the two secure-
ment methods. However, 20.9% of the patients had ery-
thema around the sutures and 9.3% of the patients had 
blood and or serous fluid discharge at the suture site.
Discussion
In this feasibility study, the new suture-free securement 
for short-term CVC performed satisfactorily as com-
pared to sutures. The overall net migration of the CVC 
was not significantly different in the study population. 
In addition, unplanned removal of the CVC was < 6% 
in both groups. Although the study was not statistically 
powered and further clinical evidence is required to eval-
uate the suture-free securement performance on a wider 
group of patients, this is encouraging data on alterna-
tive CVC securement methods to sutures. The suture-
free devices have been designed foremost to reduce the 
risk of inoculation injury, by reducing the need for using 
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sharps in the clinical environment. In the USA, 26% of 
percutaneous injuries were caused by suture needles [9]. 
Although the current study was not powered to study 
this relationship further, it is accepted that suture-free 
devices will reduce the risk of inoculation accidents and 
transmission of blood-borne pathogens, such as HIV and 
hepatitis B and C. This is reflected in current recommen-
dations [4].
Moreover, this evaluation is the first clinical study, 
to our knowledge, where daily migrations of short-
term CVC relative to the insertion site in critical care 
patients were assessed. We report that migration of 
short-term CVC occurs frequently, although the major-
ity of the movement did not result in discontinued use 
of the CVC or increased reports of adverse events. 
However, these small catheter movements occurred 
both inwards and outwards relative to the skin, which 
may facilitate the introduction of micro-organisms 
located at this site. This is consistent with the recog-
nized risk of CRI originating from micro-organisms at 
the CVC insertion site [10] and the recommended use 
of chlorhexidine dressings to decrease this microbial 
load [3, 11]. CVC migration was most likely related to 
the relative movements of the patient and the over-
all weight of the external components of the CVC, as 
was observed with 4- compared with 3-lumen CVC 
secured with sutures. These study findings support cur-
rent guidance which recommend use of a CVC with 
the minimum number of lumens and assessing the 
individual patient’s risks and benefits when selecting 
the CVC insertion site [3, 12]. Although improved sta-
bilization of CVC was achieved with a box clamp and 
additional sutures, which were applied to over 30% of 
the CVC in the suture group patients, the increased 
risk of both microbial contamination and inoculation 
injury needs to be considered against the alternative 
securement methods available for a short-term CVC. 
Suture-free CVC securement methods need to exhibit 
competitive benefit–risk profiles to sutures by offer-
ing a safe and appropriate level of patient care whilst 
meeting securement performance needs. In addition 
to the comparable catheter securement between the 
two securement systems, skin reactions including ery-
thema and swelling at the insertion site as well as the 
patient comfort level during dressing and securement 
system removal or replacement were also similar. The 
time required for applying and removing sutures and 
a dressing or suture-free device and a dressing did 
not vary significantly. However, additional time was 
required to replace the suture-free securement device 
and a dressing. The ease of replacing the suture-free 
securement system was rated worse than replacing the 
dressings only in the suture group. Securement of CVC 
with sutures and a transparent film dressing is a well-
established practice, and the lack of experience in using 
the new type of CVC securement method, as well as 
the need for replacing both the dressing and a device, 
may have influenced these results. It is however likely, 
that with experience, the time to replace the new type 
of securement system will reduce. The acquisition cost 
of the suture-free securement system (adhesive secure-
ment device plus a dressing) ranges between €6 and 
€11, depending on the type and size of the dressing, in 
comparison with €1 to €6 for the dressing alone. How-
ever, to provide an accurate cost comparison between 
the two securement methods, additional equipment 
including sterile forceps for the application of sutures, 
sterile scalpels for removal, and potentially local anaes-
thetic agent would also need to be taken into account.
In addition to the small number of patients studied, 
another limitation of this study was it only included 
ICU patients and excluded confused, excessively per-
spiring or bleeding patients who are potentially at 
greater risk of CVC migration and dislodgement. 
Patient mobility including movement in bed or walk-
ing may also influence the CVC securement and risk 
of unplanned removal of CVC. However, in this study 
no significant differences in CVC migration were found 
between patients with different levels of consciousness. 
We therefore considered that the selected study group 
of patients who were closely monitored was suitable 
for the initial assessment of the new suture-free device. 
Further clinical studies are, however, required to assess 
the suture-free device outside the critical care and also 
to broaden the patient inclusion criteria.
Conclusions
This study demonstrated frequent migration of short-
term CVC in relation to the skin insertion site. The 
new suture-free CVC securement system, evaluated 
on selected patient group in ICU, was comparable 
to sutures in securing CVC. Removing the need for 
sutures for adequately securing CVC may reduce the 
likelihood of inoculation injuries to staff and potentially 
decrease the microbial load around the CVC insertion 
site. Further clinical studies are needed to evaluate the 
suture-free CVC securement system in a wider range of 
patient groups, including those in the non-critical care 
environment.
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